Physician profile
Michael W Grainger
NPI 1861439937
$7,277.38
in general payments reported to CMS, 2019-2025
43 companies · $914 in 2025
The $914 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $695 · 2020: $568 · 2021: $1,324 · 2022: $1,031 · 2023: $1,410 · 2024: $1,335 · 2025: $914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,635 · Education: $24.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,635.06 |
| Education | $24.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,468.96 | 2019-2025 | |
| Glaxosmithkline, LLC. | $781.75 | 2019-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Lilly USA, LLC | $780.94 | 2020-2025 | Jardiance, Mounjaro, Emgality |
| Novo Nordisk INC | $622.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $364.78 | 2019-2025 | |
| Astellas Pharma US INC | $296.75 | 2020-2025 | Veozah |
| Amgen INC. | $286.52 | 2019-2025 | Otezla, Repatha, Prolia |
| Novartis Pharmaceuticals Corporation | $286.33 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.05 | 2019-2025 | Jardiance, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $256.19 | 2019-2025 | Xifaxan |
| Relievant Medsystems, INC. | $201.95 | 2021 | |
| Gilead Sciences, INC. | $182.59 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $169.67 | 2019-2023 | Fasenra |
| Axsome Therapeutics, INC. | $122.95 | 2023-2024 | Auvelity |
| Janssen Pharmaceuticals, INC | $119.45 | 2019-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Grainger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.